Women's Cancer News
Feb. 26, 2014

Bevacizumab prolongs survival in advanced cervical cancer
USA Today
The drug bevacizumab helps women with advanced cervical cancer live nearly four months longer, according to a new study that's predicted to change the standard of care for the disease. Women who combined bevacizumab and chemotherapy lived a median of 17 months after diagnosis, while those who received chemo alone lived 13.3 months, according to a study of 452 women in the New England Journal of Medicine. Just two decades ago, women with advanced cervical cancer lived only eight or nine months, says lead author Krishnansu Tewari, a professor of gynecologic oncology at the University of California Irvine Medical Center.More

Removing ovaries cuts risk of death in gene carriers
USA Today
Women who inherit mutations in high-risk genes that sharply increase the risk of breast or ovarian cancer can reduce their risk of death by 77 percent by having their ovaries removed by age 35, a new study shows. The study involved mutations in the genes BRCA1 and BRCA2, which cause 5 percent to 10 percent of breast cancers and 15 percent of ovarian cancers, according to the National Cancer Institute.More

Previous CIN3 diagnosis doubled cervical, vaginal cancer mortality risk
Women previously treated for cervical intraepithelial neoplasia grade 3 were more than twice as likely to die from cervical or vaginal cancers than the general population, according to results of a population-based cohort study. Researchers conducted the study to identify the factors that influenced long-term risks for the development of or mortality from invasive cervical or vaginal cancers.More

HPV vaccination impacts lesion risk
HealthDay News via MPR
Vaccination with the quadrivalent human papillomavirus (HPV) vaccine is associated with reduced risk of atypia or worse (atypia+) or cervical intraepithelial neoplasia grade 2 or 3 (CIN2/3), according to a study published online February 19 in the Journal of the National Cancer Institute. Birgitte Baldur-Felskov, M.D., from the Danish Cancer Society Research Center in Copenhagen, and colleagues assessed the risk of cervical lesions subsequent to HPV vaccination using data from nationwide registries for all girls and women born in Denmark from 1989–1999. Using linkage to the nationwide Pathology Data Bank, incident cases of cervical lesions were identified.More

Philadelphia hospital restricts morcellation procedure
The Wall Street Journal (Subscription requred)
Temple University Hospital has issued what appear to be the tightest restrictions yet on a common gynecological surgical procedure used during many hysterectomies, which has come under close scrutiny because of the potential to spread cancer in rare cases.More

Circulating tumor DNA shows versatility in cancer screening and prognosis
BioNews Texas
Scientists from a number of institutions have found a promising new way to non-invasively screen for early-stage cancers using tiny fragments of DNA shed by tumors into the bloodstream. These circulating tumor DNA (ctDNA) strands were detected in more than 75 percent of patients studied by the team. The study consisted of 640 patients with various types of cancer, and the cancers that most often presented ctDNA were advanced pancreatic, ovarian, colorectal, bladder, gastroesophageal, breast, melanoma, liver, head, and neck.More

Molecular tech helps doctors target cancer cells from the inside
A group of American researchers may have revolutionized how we treat cancer, thanks to molecular technology that can target diseased cells from the inside. The study tested the effect of nanomotors, miniscule devices that turn energy into motion, on live cells. Scientists found that they could potentially be used to deliver drugs non-invasively, or perform surgery inside of cells. More